NCT07833410Recruiting
Chinese Multicenter Cohort Study of Intracerebral Hemorrhage
Chinese Multicenter Prospective Cohort Study of Intracerebral Hemorrhage
Source: ClinicalTrials.gov · Last updated 22 Sept 2026
Brief summary (registry, in English)
Spontaneous intracerebral hemorrhage is a severe form of stroke associated with high mortality and long-term disability. The Chinese Multicenter Cohort Study of Intracerebral Hemorrhage (CASA) is a prospective observational patient registry designed to enroll approximately 10,000 adults with imaging-confirmed spontaneous intracerebral hemorrhage and 2,000 adult healthy controls at more than 30 hospitals in China. The study will collect standardized clinical, laboratory, neuroimaging, lifestyle, and treatment data together with ethically approved blood, urine, and other biospecimens. Participants with intracerebral hemorrhage will be followed at 3 months, 6 months, and annually for up to 10 years. The primary objective is to characterize and identify determinants of the full distribution of modified Rankin Scale scores at 90 days. Secondary objectives include evaluating 90-day unfavorable functional outcome defined as mRS 4-6, recurrent intracerebral hemorrhage and mortality, identifying clinical and molecular biomarkers, and developing and externally evaluating multimodal prognostic models. The study does not assign treatment; all clinical care is determined by treating clinicians.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 12000 (estimated)
- First submitted
- 14 Sept 2026
- Start date
- 1 Feb 2024
- Primary completion date
- 31 Mar 2029
- Lead sponsor
- Xiangya Hospital of Central South University
- Diseases
- Stroke
- NCT number
- NCT07833410
What you commit to
- Study type: Observational
- Planned participants: 12000
- From 1 Feb 2024 to the primary completion date, 31 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Neurologic disease, particularly any prior intracerebral hemorrhage.
Other illness
- Traumatic intracerebral hemorrhage.
- Secondary intracerebral hemorrhage attributed to an arteriovenous malformation, ruptured aneurysm, moyamoya disease, cavernous malformation, hematologic disorder, hemorrhagic tumor, vasculitis, cerebral venous thrombosis, hemorrhagic transformation of cerebral infarction, or other prespecified secondary cause.
- Mixed intracerebral hemorrhage involving multiple deep and lobar locations at onset.
- Severe psychiatric disease that precludes study procedures or follow-up.
- End-stage hepatic or renal failure.
- Autoimmune disease judged by the investigator to materially affect study objectives.
- Active malignant tumor.
- Any other condition that the investigator judges makes participation inappropriate.
- Malignant tumor.
- Any other condition that the investigator judges makes participation inappropriate.
Other
- Pregnancy.
Who the study is looking for
- Age 18 years or older.
- Intracerebral hemorrhage confirmed by head computed tomography and/or magnetic resonance imaging.
- Hemorrhage located in a deep cerebral region, cerebral lobe, cerebellum, or brainstem.
- Presentation to a participating hospital within 30 days after symptom onset.
- Written informed consent and broad consent provided in accordance with the ethics-approved process.
- Age 18 years or older.
- Able to provide written informed consent.
- No known history of intracerebral hemorrhage.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiangya Hospital Central South University Coordinator of this site? Confirm its status | Changsha | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.